U.S.-based Biomarin Pharmaceutical Inc.’s treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.
One U.S. biotech company is celebrating Independence Day weekend with a fresh $1 billion in cash from a corporate partner, which it was able to secure without giving up its […]
